Insider · CIK 0001818802

Atillasoy Ercem

Reports to the SEC for 1 company · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001818802

Forms 4 and 5

Insider transactions

19 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2022-10-21	KLRSKalaris Therapeutics, Inc.S Sale	See Remarks	SSale	−1,527 sh	$8.48	−$13K	131,372
2022-10-20	KLRSKalaris Therapeutics, Inc.S Sale	See Remarks	SSale	−1,527 sh	$8.48	−$13K	131,372
2022-10-20	KLRSKalaris Therapeutics, Inc.S Sale	See Remarks	SSale	−568 sh	$9.36	−$5,316.878	132,899
2022-10-19	KLRSKalaris Therapeutics, Inc.S Sale	See Remarks	SSale	−568 sh	$9.36	−$5,316.878	132,899
2022-07-21	KLRSKalaris Therapeutics, Inc.S Sale	See Remarks	SSale	−1,533 sh	$5.38	−$8,245.087	133,467
2022-07-20	KLRSKalaris Therapeutics, Inc.S Sale	See Remarks	SSale	−563 sh	$5.21	−$2,935.764	135,000
2022-07-01	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+26K sh	—	—	26,000
2022-07-01	KLRSKalaris Therapeutics, Inc.A Award	See Remarks	AAward	+14K sh	—	—	135,563
2022-04-21	KLRSKalaris Therapeutics, Inc.S Sale	See Remarks	SSale	−1,587 sh	$5.86	−$9,300.614	121,563
2022-04-20	KLRSKalaris Therapeutics, Inc.S Sale	See Remarks	SSale	−453 sh	$6.68	−$3,027.988	123,150
2022-01-25	KLRSKalaris Therapeutics, Inc.S Sale	See Remarks	SSale	−4,639 sh	$8.24	−$38.2K	100,347
2022-01-18	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+56.7K sh	—	—	56,744
2022-01-18	KLRSKalaris Therapeutics, Inc.A Award	See Remarks	AAward	+23.3K sh	—	—	123,603
2021-10-21	KLRSKalaris Therapeutics, Inc.S Sale	See Remarks	SSale	−1,514 sh	$24.23	−$36.7K	104,986
2021-01-19	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+52K sh	—	—	52,000
2021-01-19	KLRSKalaris Therapeutics, Inc.A Award	See Remarks	AAward	+28K sh	—	—	106,500
2020-08-03	KLRSKalaris Therapeutics, Inc.P Purchase	See Remarks	PPurchase	+3,500 sh	$17.00	+$59.5K	78,500
2020-07-29	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+407K sh	—	—	407,400
2020-07-29	KLRSKalaris Therapeutics, Inc.A Award	See Remarks	AAward	+75K sh	—	—	75,000

Recent filings

Accepted (ET)
Oct 264/A
Atillasoy Ercem0000899243-22-034264
SEC(opens sec.gov)
Oct 244
Atillasoy Ercem0000899243-22-034054
SEC(opens sec.gov)
Jul 224
Atillasoy Ercem0000899243-22-026579
SEC(opens sec.gov)
Jul 214
Atillasoy Ercem0000899243-22-026517
SEC(opens sec.gov)
Jul 64
Atillasoy Ercem0000899243-22-025232
SEC(opens sec.gov)
Apr 224
Atillasoy Ercem0000899243-22-015392
SEC(opens sec.gov)
Apr 44
Atillasoy Ercem0000899243-22-013336
SEC(opens sec.gov)
Jan 264
Atillasoy Ercem0000899243-22-003264
SEC(opens sec.gov)
Oct 254
Atillasoy Ercem0000899243-21-041423
SEC(opens sec.gov)
Jan 214
Atillasoy Ercem0000899243-21-002768
SEC(opens sec.gov)
Aug 54
Atillasoy Ercem0000899243-20-021575
SEC(opens sec.gov)
Jul 314
Atillasoy Ercem0000899243-20-020912
SEC(opens sec.gov)

Companies

Kalaris Therapeutics, Inc.See RemarksKLRS

Address

C/O ALLOVIR, INC. 139 MAIN STREET, SUITE 500

CAMBRIDGE, MA, 02142